Chao, Ariana M.; Wadden, Thomas A.; Berkowitz, Robert I.; Quigley, Kerry; Silvestry, Frank published the artcile< The risk of cardiovascular complications with current obesity drugs>, SDS of cas: 96829-58-2, the main research area is cardiovascular complication obesity drug pharmacotherapy; Cardiovascular; cardiovascular disease outcomes; obesity; pharmacotherapy; weight loss.
IntroductionObesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased phys. activity in adults. These medications result in clin. significant weight losses, as well as improvements in some cardiometabolic risk factors. Areas coveredWe briefly review the history of anti-obesity medications (AOMs) as related to cardiovascular safety, and summarize weight loss efficacy and cardiovascular data from clin. trials of orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide. Expert opinionCurrent AOMs approved for chronic weight management have generally favorable effects on some cardiometabolic parameters. However, the long-term safety of orlistat, phentermine/topiramate, and naltrexone/bupropion on cardiovascular morbidity and mortality have not been established. The cardiovascular safety of liraglutide, at a dose of 1.8 mg/d, was demonstrated in a large randomized outcomes trial in participants with type 2 diabetes.
Expert Opinion on Drug Safety published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, SDS of cas: 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics